Mazen Noureddin, MD, MHSc
@NoureddinMD
Prof of Med, Hepatologist @Methodisthosp. Researcher, Dir Houston Research Institute. Father to 2 girls. AE @AGA_CGH
Great topline data by Neuraly Inc. DD01 (Dual GLP-1/Glucagon) in MASH patients! More option for our patients on the way!! Thanks to the patients, investigators and Summit Clinical Research Pinnacle Clinical Research for making this possible #livertwitter businesswire.com/news/home/2025…
Keep an eye out for the @GuildConference brochure and register! Puerto Rico or Maui. New for 2026: 1. APP Scholars will be going to Puerto Rico 2. GI Fellow Scholars will remain at Maui guildconference.com/2026/
A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis @JVLazarus @TheLancet @geneyim @AlkhouriNaim pubmed.ncbi.nlm.nih.gov/40672054/
Today, @NEJM reports that Efruxifermin (an FGF21 agonist) is the first drug to reduce fibrosis in compensated cirrhosis due to NASH. This effect is seen after 96 weeks, so patience is key. Could combining Semaglutide make it even more powerful?
How @MayoClinicFLGIH does liver conferences! @AndrewKeavenyMD
Combination Therapy of TERN-501 and TERN-101 (THR-B and FXR) are now published @NatureMedicine @AlkhouriNaim @DrLoomba #livertwitter @NoureddinNabil @NASH_and_coffee @SekiEki nature.com/articles/s4159…
Happening now in SDCC 32 @DDWMeeting #Obesity and Advanced #LiverDisease With @NoureddinMD moderating @juanpabloarab discussing #ETOH and obesity @PuneetPuri18 discussing #AOM & #MASH I will discuss the role of treatments that don’t also impact obesity in MASH 🤔
#Semaglutide phase 3 data in patients with #MASH now in @NEJM improvement in Histology #liver #livertwitter
In this interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results: nej.md/3EVFAFM
Pleasure to be with my friend and our international expert @drjoegalati on his radio show tonight @iHeartRadio #livertwitter #gitwitter
Tune the tonight on iHeartRadio and listen to my friend and colleague @NoureddinMD discuss the latest in fatty liver disease. #fattyliver #masld #talkradio #iHeartRadio
Amazing group to work with #livertwitter
Our team is hiring! If you want to help transform the care of people living with alcohol-associated liver disease (ALD) through research. Please join us: We are looking for a Research Program Manager for the ALD team at @VCU_Liver More details: tinyurl.com/28ey49uy
Good morning from Pittsburgh @AHNGastro @ebtapper @JasmohanBajaj #academiclife
Had a great time @APASLnews and visiting the great wall #China
Last session of the @AASLDtweets ETC on MASLD, MetALD and ALD. @norahterrault is speaking on how to recruit PTs in MetALD trials. @MajaThiele @AlkhouriNaim @juanpabloarab @AleksanderKrag @betelm #livertwitter
Excited and honored to be hosting @AHNGastro's Annual GI and Liver Summit on April 5th. So looking forward to hosting and learning from @shifaumarMD, @AliRezaieMD, @ScottGabbardMD, @AfrinKamalMD, @AtoosaRabiee, @JasmohanBajaj, @ebtapper, @NoureddinMD and so many more!
📅 Happening this month! Don’t miss this unparalleled opportunity to dive deep into the most pressing challenges and innovations in #MASLD, #MetALD and #ALD. View the program and register now! #LiverTwitter @juanpabloarab @NoureddinMD bit.ly/4gq0PNN
Last chance to register for the MetALD, MASLD and ALD conference in Las Vegas! We hope you can join us #LiverTwitter #GITwitter #SLD @AlkhouriNaim @AlinaAllenMD @DrLoomba @AleksanderKrag @EASLnews @AASLDtweets @DrMTLong @QAnstee @saulkarpen @WRayKimMD @AASLDPresident…
Still time to register! Get the latest on #MASLD, #MetALD, and #ALD in Las Vegas with three days of expert-led sessions at AASLD's Emerging Topic Conference. Secure your spot: bit.ly/3EJV6Ec #LiverTwitter @juanpabloarab @NoureddinMD
We are running out of spots so register now for MASLD, MetALD and ALD conf this month in Vegas by @AASLDFoundation #livertwitter
📅 Happening this month! Don’t miss this unparalleled opportunity to dive deep into the most pressing challenges and innovations in #MASLD, #MetALD and #ALD. View the program and register now! #LiverTwitter @juanpabloarab @NoureddinMD bit.ly/4gq0PNN
When in Rome!! Dinner outdoor at the old city of Rome with these folks @ArunJSanyalVCU @schattenbergJ @AlkhouriNaim #livertwitter
What a day in the history of MASH! Reversal of Fibrosis in MASH cirrhotics by 24% (paired) and 17% (ITT) all sig P values. Same for NITs!!!! Happy for the our patients. FGF21s are here to stay!! #livertwitter @ebtapper @AlkhouriNaim @akerotx globenewswire.com/news-release/2…
🥃 Our new article in @ACERjournal AUD, ALD, and alcohol-related liver cancer mortality 📈rising in the US older adult, despite global declines 🔗 shorturl.at/Likyz @l_suthat @KarnJUVE @LuisAntonioDiaz @juanpabloarab @NoureddinMD
Increased mortality from alcohol use disorder, alcohol-associated liver disease, and liver cancer from alcohol among older adults in the United States: 2000 to 2021 doi.org/10.1111/acer.1…